Section
A digital standardized skin care regimen improves clearance rates, reduces relapse, and enhances quality of life in acne-rosacea comorbidity, mediated partially by epidermal barrier restoration.
A multicenter cohort study demonstrates that circulating tumor DNA (ctDNA) is more accurate than Merkel cell polyomavirus (MCPyV) antibody testing in detecting recurrence of Merkel cell carcinoma, improving patient surveillance and risk str
This cohort study reveals differential melanoma survival outcomes linked to institutional settings and insurance types, highlighting the need for standardized care in advanced melanoma stages.
This article addresses common patient misconceptions about hyaluronic acid fillers, elucidating safety, efficacy, and best practice strategies to ensure natural results and improved patient trust.
This article reviews a retrospective study evaluating the feasibility and outcomes of a 24-week abrocitinib tapering regimen in moderate-to-severe atopic dermatitis, comparing dose reduction versus interval extension approaches and their im
A multidisciplinary Delphi panel offers practical, consensus-based recommendations to standardize when and how to use staging and surveillance imaging for localized cutaneous squamous cell carcinoma (CSCC).
This study evaluates the successful 24-week tapering of abrocitinib in moderate-to-severe atopic dermatitis patients, comparing dose reduction versus interval extension tapering regimens and demonstrating high feasibility with substantial d
This retrospective analysis demonstrates high-frequency ultrasound’s efficacy in diagnosing palpable indurations post-cosmetic filler injection, enabling tailored treatment strategies that improve clinical outcomes and minimize intervention
A large meta-analysis found JAK-STAT inhibitors slightly increased influenza, bronchitis, and herpes zoster risk, especially in atopic dermatitis, while serious and opportunistic infections were not significantly increased.
In this multicentre cohort of 207 hospitalized adults with DRESS, 17% required ICU care. Hospital-acquired DRESS and greater clinical severity independently predicted ICU admission, while ICU mortality reached 20%.
A single-center validation study suggests the CTCL-PRO-20 may provide a reliable, disease-specific measure of quality of life in patients with cutaneous T-cell lymphoma.
This article provides an in-depth exploration of scrotal lymphedema and hyperhidrosis, detailing their physiological causes, clinical symptoms, and the latest management strategies for both patients and healthcare providers.
A pilot randomized controlled trial and translational study demonstrate that Sopoongsan (SPS) effectively reduces chronic upper body pruritus in atopic and seborrheic dermatitis by inhibiting STAT1-mediated inflammatory pathways, offering a
The RAAINBOW phase II/III trial demonstrates that Cinainu, a topical botanical solution, significantly improves hair regrowth and quality of life in paediatric patients with moderate-to-severe alopecia areata, offering a well-tolerated alte
This review evaluates TPM203, a novel nanoparticle-based therapy for Pemphigus Vulgaris, detailing its safety profile, rapid pharmacokinetics, and ability to modulate regulatory T-cell and memory B-cell populations to induce immune toleranc
This review synthesizes 2-year results from the BE HEARD phase 3 trials and their extension, demonstrating that dual IL-17A/F inhibition with bimekizumab provides deep, durable clinical responses and a favorable safety profile for patients
The multicentre phase II PROMIT trial demonstrates that intermittent dacarbazine can sensitize BRAF wildtype metastatic melanoma patients with primary ICI resistance to subsequent ICI rechallenge, yielding an 18% objective response rate and
A Phase IIb clinical trial demonstrates that pumecitinib 3% gel significantly improves skin clearance in adults with mild-to-moderate atopic dermatitis. Twice-daily application proved superior to once-daily dosing, maintaining a favorable s
The SHINE trial, despite missing its primary endpoint due to a high placebo response, suggests that high-dose vilobelimab significantly reduces draining tunnels in moderate-to-severe hidradenitis suppurativa, offering a potential new therap
This review synthesizes the 52-week pooled results from two Phase 3 trials, detailing the pharmacokinetics, safety, and biomarker responses of secukinumab in moderate-to-severe hidradenitis suppurativa.
